PCSK9 and familial hyperaldosteronism: The consistent and significant LDL-C reductions observed with PCSK9 inhibitors in this review, often exceeding 50%, and with up to 90% of patients meeting target goals in some trials, highlight the potential for these agents to bridge therapeutic gaps in high-risk populations, such as those with FH, diabetes, or statin intolerance [23].